Trial Profile
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms NICCI
- 18 Dec 2021 Status changed from active, no longer recruiting to completed.
- 18 Dec 2021 Status changed from active, no longer recruiting to completed.
- 16 Oct 2019 Status changed from recruiting to active, no longer recruiting.